NVDA+2.54%AAPL+1.32%GOOGL−1.62%MSFT+0.20%AMZN−0.10%TSM+1.60%SPCX+7.79%META+0.47%
StockVS

NYSE American · Biotechnology · USD

Pelthos Therapeutics Inc. (PTHS) Stock Analysis

Pelthos Therapeutics Inc. (PTHS) is a Biotechnology stock listed on NYSE American and quoted in US Dollar.

Last Updated: October 21, 2026

PTHS

$18.70

−$1.80 (−8.78%)

Oct 21, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare PTHS with… →

PTHS Key Statistics

As of Oct 21, 2026
Trading
Open
$20.47
Previous Close
$20.50
Day's Range
18.70–20.54
52-Week Range
18.19–37.50
Volume
99.13K
BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
3.11
Valuation
Market Cap
$71.59M
P/E Ratio
unprofitable
P/S ratioMarket value divided by annual revenue. Useful for companies that are not yet profitable, where a P/E cannot be calculated.
1.65
EPS (ttm)Profit attributable to each share over the last twelve months.
−27.53
Financials (FY)
Revenue (FY)
$16.80M
Net Income (FY)
−$43.32M
Profit marginThe share of revenue left as profit after all costs and taxes.
−199.50%
Shares OutstandingThe total number of shares held by all investors. Market value is this figure multiplied by the share price.
3.83M
1-Year Return
−39.68%
Dividend and dates
Earnings Date
November 12, 2026
Avg Volume
61.08K

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

Key facts

As of October 21, 2026, PTHS closed at $18.70, −39.68% over 1 year.

Pelthos Therapeutics Inc. (PTHS) has a market capitalization of $71.59M.

In fiscal 2025, PTHS reported revenue of $16.80M.

PTHS Stock Return by Calendar Year

Pelthos Therapeutics Inc. (PTHS) return since Feb 2024: what $10,000 became

1 year
$10,000 $6,032
−39.68%
Since Feb 2024
$10,000 $3,896
−61.04%

If you had invested $10,000 in Pelthos Therapeutics Inc. (PTHS) at the close on February 16, 2024, the earliest close on record here, it would have been worth $3,896 at the close on October 21, 2026: −61.04% in total, −29.68% a year, over a partial period shorter than 10 years. A historical calculation from closing prices adjusted for splits and dividends, before fees and taxes.

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

YearReturn
2026 (partial year)−39.68%
2025+383.62%
2024 (partial year)−86.65%

As of October 21, 2026.

PTHS Revenue and Earnings by Fiscal Year

FY ends December
Fiscal yearRevenueNet incomeNet margin
2025$16.80M−$43.32M−257.9%
2024$0.00−$7.96M—
2023$0.00−$7.38M—
2022$0.00−$2.46M—
Fiscal yearRevenueGross profitOperating incomeNet incomeNet margin
2025$16.80M$7.43M−$32.43M−$43.32M−257.9%
2024$0.00$0.00−$7.57M−$7.96M—
2023$0.00—−$6.86M−$7.38M—
2022$0.00—−$2.32M−$2.46M—

Annual figures as reported, in the company's reporting currency. As of December 31, 2025.

PTHS Valuation vs Biotechnology Median

Median of 608 stocks
MetricPTHSBiotechnology medianvs median
P/S ratio1.6513.300.1x the median
Profit margin−199.50%−38.31%161.2 pts below

Medians across 608 Biotechnology stocks that report the metric. Medians, not averages, so one outlier cannot move them. As of October 21, 2026.

Recent News

All 7 articles ↓

News provided by third-party sources. Not financial advice.

Analysis

Data-derived

Company Overview

Pelthos Therapeutics Inc. (PTHS) carries a market capitalisation of $71.59M. It is classified in the Biotechnology industry, within the Healthcare sector. Headcount on file is 92.

Over the past 52 weeks the price has ranged from $18.19 to $37.50. The most recent close on file for PTHS is $18.70, dated October 21, 2026. That is −$1.80 (−8.78%) against the previous close. The latest close sits 2.8% above that 52-week low.

Financial Health

The most recent full year on file, fiscal 2025, shows revenue of $16.80M. The same year closed with a net loss of $43.32M. Profit margin runs at −199.5%. That is 161.2 percentage points below the Biotechnology median of −38.31%. Trailing earnings per share are −27.53.

Across the 4 fiscal years on file, revenue moves from $0.00 in 2022 to $16.80M in 2025. Of those 4 years, 0 report positive net income.

Valuation Assessment

The record shows negative trailing earnings, so no price-to-earnings ratio is published. The price-to-sales ratio is 1.65. On price-to-sales that is 0.1 times the Biotechnology median of 13.3. 608 Biotechnology companies report these metrics, and the medians quoted come from that group.

The reported beta is 3.11. Daily returns over the trailing 2 years annualize to a volatility of 143.76%. Over the trailing twelve months the total return is −39.68%. The stored price history starts on February 16, 2024, and the total return since then is −61.04%.

Growth & Income

No dividend is on file for PTHS.

The record holds one complete calendar year, 2025, which returned +383.62%. So far in 2026 the total return is −39.68%.

Peer Comparison

Pelthos Therapeutics Inc. (PTHS) operates in the Biotechnology industry. Here is how it compares to its closest peers by market capitalization:

Company Ticker Market Cap P/E Ratio
Pelthos Therapeutics Inc. PTHS $71.59M —
Vertex Pharmaceuticals Incorporated VRTX $132.95B 30.4
Moderna, Inc. MRNA $98.14B —
Regeneron Pharmaceuticals, Inc. REGN $82.95B 19.9

The Biotechnology industry average P/E ratio is 16.6x. Pelthos Therapeutics Inc. has no P/E ratio because it is not currently profitable.

Every figure above is read from this page's own data on each daily rebuild. Informational only, not financial advice. As of October 21, 2026.

Related Biotechnology Stocks

VRTX

Vertex Pharmaceuticals Incorporated

$132.95B

 MRNA

Moderna, Inc.

$98.14B

 REGN

Regeneron Pharmaceuticals, Inc.

$82.95B

 ARGX

argenx SE

$55.97B

 ONC

BeOne Medicines AG

$43.97B

 RVMD

Revolution Medicines, Inc.

$41.64B
View all Biotechnology stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.13T

 JNJ

Johnson & Johnson

$621.22B

 ABBV

AbbVie Inc.

$503.27B

 UNH

UnitedHealth Group Incorporated

$374.30B

 MRK

Merck & Co., Inc.

$369.78B
View all Healthcare stocks →

About Pelthos Therapeutics Inc.

Pelthos Therapeutics Inc., a bio-pharmaceutical company, develops and commercializes therapeutic products to help patients with unmet treatment burdens. The company offers ZELSUVMI for the treatment of molluscum contagiosum in adults and children 1 year of age and older; XEPI, (ozenoxacin) cream, a quinolone antimicrobial for the treatment of impetigo due to Staphylococcus aureus or Streptococcus pyogenes in adult and pediatric patients 2 months of age and older; and XEGLYZE, a pediculicide indicated for topical treatment of head lice infestation in patients 6 months of age and older. It also provides NITRICIL, a proprietary nitric oxide-based technology platform. The company was formerly known as Channel Therapeutics Corporation and changed its name to Pelthos Therapeutics Inc. in July 2025. Pelthos Therapeutics Inc. was founded in 2002 and is based in Durham, North Carolina.

Visit website →